Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acorda Therapeutics Inc
NASDAQ ACORQ
Data sourced from
and
and
Acorda Therapeutics Inc Retained Earnings To Equity Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: 152.88%
Acorda Therapeutics Inc Retained Earnings To Equity Ratio 1 year YoY Change (%) is 152.88% for the quarter ending March 31, 2024. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
-
Acorda Therapeutics Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2023 was -12.38.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ACORQ
| CEO | - |
| IPO Date | Feb. 10, 2006 |
| Location | United States |
| Headquarters | 2 Blue Hill Plaza, Pearl River, NY, United States, 10965 |
| Employees | 102 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email